food noise stopped around month 3 on 10mg. i’ve noted that before. what i haven’t logged is that libido dropped in the same window, and i’ve been sitting with that for about six weeks. 39, not perimenopausal by any marker i can see, sleeve since 2017, tirz since march 2024. no obvious hormonal explanation. but GLP-1 receptors aren’t just gut - they’re hypothalamic, and the hypothalamus runs appetite, reward, and sexual motivation through overlapping circuitry. the quieting might not be selective.
what i don’t know is whether this is dose-dependent (holding 10mg, not pushing to 12.5) or whether it levels out over time. my NUT said she’s heard this from other post-sleeve patients on these meds but didn’t have data. the literature doesn’t either - post-bariatric patients are excluded from most dose-response trials, so this particular combination is basically undocumented. observation-based, n=1. curious if anyone else hit this at the same dose and timing window.
The “basically undocumented” part undersells your NUT’s data, honestly. Other post-sleeve patients reporting the same thing is real evidence, just not the RCT kind. The piece I’d actually question though: when did month 3 land relative to your dose escalation? I stalled hard at 7.5mg for seven weeks, and things shifted when I stopped titrating up.
Sitting with that for six weeks before posting is honestly the part that stood out to me, that’s a long quiet observation window and it changes how I’d read your data. I want to add a dimension that hasn’t come up yet, with the caveat that I’m on sema not tirz, no sleeve, week 18, so this is read-across rather than lived. Two layers worth checking that sit underneath the hypothalamic-circuitry frame, both from the bariatric literature I’ve been borrowing from since my own fasting insulin and hsCRP shifts surprised me earlier this year. First, micronutrient status. Post-sleeve patients on GLP-1s are running a stacked absorption deficit, the sleeve already drags B12, iron, zinc and vit D over the long arc, and then suppression cuts intake further on top. Zinc specifically tracks with libido in the few studies that have looked at women in this range, and it’s the kind of thing that won’t show on a standard panel unless someone asks for it. Six weeks of quiet food noise on top of nine years post-sleeve is a window where I’d want a current zinc, ferritin, B12, vit D and free T pulled before attributing the change purely to central reward circuitry. The mechanism your NUT and you are both reaching for might be sitting downstream of something quieter. Second, the fat loss itself. Adipose stores and aromatizes sex hormones, and rapid loss shifts SHBG and free hormone availability. The literature on the postpartum lymphatic and hormonal clearance window has bits on this, but it carries over to any fast loss period in women our age. If you’ve moved a meaningful amount since March 2024, that’s a hormonal variable independent of receptor signalling, and worth flagging to whoever orders your bloods. I’d hold the 10mg, ask your GP for those bloods, and give it another cycle or two before calling the pattern. The “does it level out” question won’t answer in less than three months in my experience watching friends sit through similar windows, the standard guidance is usually shorter than what actually plays out. What did your last set of bloods include, and when were they pulled?
there’s a distinction between evidence that exists and evidence that’s accessible, and that’s the gap “undocumented” is pointing at. anecdotes spread across individual practitioners’ patient panels don’t compound into something you can examine, compare across dose levels, or adjust for GI anatomy variation. the NUT’s observations being real doesn’t close that gap. on the timing question: i’ve been holding at 10mg, not actively titrating. month 3 on the hold is when this showed up, not month 3 of escalation. your experience of things shifting when you stopped titrating is a different pharmacokinetic event than a stable-dose window - the circulating levels look different, the receptor occupancy pattern is different. those are interesting data points but i don’t think they map directly onto what i’m describing.
Post-bariatric SHBG tanks during weight loss, and month 3 on stable tirz is exactly when that effect compounds. tbh Independent mechanism from the GLP-1 receptor story, but same timing. Could account for all of the libido drop or part of it. Recent labs would tell you - the binding globulin number usually clarifies whether that’s loaded into the picture.
the receptor overlap framing is fair and i don’t think you’re wrong that it’s plausible, hypothalamic GLP-1 expression is real and the appetite/reward circuitry isn’t cleanly partitioned. but “not perimenopausal by any marker i can see” is the part i’d push on, because at 39 a single FSH or a normal panel doesn’t rule it out. FSH is cycle-day dependent and bounces around the perimenopause window for years before settling, AMH drops well ahead of symptoms, and a regular cycle is the slowest marker to go. clinical perimenopause is a pattern over months, not a lab result. the other piece you haven’t named is SHBG. rapid fat loss reliably pushes SHBG up, which drops free testosterone in women, and free T tracks libido more than total does. you’re 14 months into tirz with real weight loss on top of an already-altered post-sleeve baseline, so the month 3 on 10mg window you’re flagging also lines up with whatever fat loss compounded on the most recent titration. that doesn’t kill the hypothalamic story, it just means there’s a well-characterized mechanism sitting in front of it that doesn’t require a novel one. fwiw the GLP-1 obesity trial pop did capture sexual function shifts, mostly improvements at the group mean, but those means are confounded by weight loss itself and the tails get hidden. a drop at your specific dose/timing window is consistent with the literature, the question is which mechanism is actually doing the work for you. worth getting SHBG, free T, FSH, estradiol, and AMH before you sit with the receptor hypothesis for another six weeks. subtract them from the differential first. n=1 with three plausible mechanisms running in parallel isn’t really n=1, it’s three n=1s tangled together.
Dopaminergic reward circuitry doesn’t distinguish food-seeking from other motivated behaviors at the receptor level, so “the quieting might not be selective” is accurate mechanism, not speculation. GLP-1 receptor activation in the nucleus accumbens that suppresses eating behavior in animal models runs through the same pathways as sexual motivation - they share signal architecture, not just anatomical proximity. I noticed something adjacent during my February break - three weeks off tirz and it wasn’t just hunger that came back w/ information attached. I didn’t track it carefully enough to hand you a usable data point, but the pattern was there. Holding at 10mg rather than pushing to 12.5 seems right for a reason you might not be weighting heavily: if this is dose-dependent and suppression-driven, escalating is testing in the wrong direction. And the post-bariatric exclusion from trials is the real structural gap here - no clean data on whether sleeve physiology alters GLP-1 receptor sensitivity thresholds in ways that make off-target suppression more pronounced at doses that wouldn’t register this way in a standard population. Your NUT’s anecdotal pattern from other post-sleeve patients is probably the most specific signal available right now, even without quantification behind it. The fact that she’s hearing it from others at similar timing is itself a pattern, even if it’s not a study.